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Background:
We have previously suggested that N-terminal pro brain natriuretic peptide (Nt-proBNP) is a cardiovascular risk factor in hypertension. We wanted to test this hypothesis in a new larger group of patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy. Methods: In 945 hypertensive patients from the LIFE study, we measured traditional cardiovascular (CV) risk factors, urine albumin/creatinine ratio (UACR) and Nt-proBNP by immunoassay after two weeks of placebo treatment. The patients were followed for 55±0.6 months recording the composite endpoint (CEP) of CV death, non-fatal stroke or non-fatal myocardial infarction. Results: Nt-proBNP above the median value of 20.1 pmol/l was associated with more CV events (Table 1 ). In Cox regression analyses log(Nt-proBNP) (hazard ratio (HR)=2.40 per 10-fold increase**) predicted CEP independently of total serum cholesterol (HR=1.37 per mmol/l**), serum high density lipoproteins (HR=0.50 per mmol/l*) and logUACR (HR=1.86**). CV death was predicted by log(Nt-proBNP) (HR=3.07 per 10-fold increase**) independently of total serum cholesterol (HR=1.69 per mmol/l***) and of logUACR (HR=2.31** Background: The ECG strain pattern of downsloping convex ST segment with inverted asymmetrical T-wave in leads V5 or V6 is associated with increased risk of cardiovascular (CV) morbidity and mortality in the overall LIFE study population. African Americans (AA) have higher rates of ECG strain, CV and all-cause mortality in LIFE, but whether ECG strain is associated with increased risk in AA is unclear. Methods: Baseline ECGs were examined in 8,854 hypertensive patients (515 [5.8%] AA) enrolled in LIFE. All patients were treated in a blinded manner with atenolol-or losartanbased regimens and followed for a mean of 4.7±1.1 years. Results: AA patients had a higher prevalence of ECG strain (27.8 vs 9.9%, p<.001), were younger, more likely to be male, current smokers, diabetic, have a history of ischemic heart disease, stroke or congestive heart failure, had higher Sokolow-Lyon voltage but lower Cornell products and greater albuminuria. In non-AA patients, strain was associated with higher 5-year event rates of CV mortality, myocardial infarction (MI), stroke, allcause mortality, and the LIFE composite endpoint of CV mortality, MI or stroke (Table) . In contrast, AA patients with and without strain had similar rates of all endpoints except MI. These findings persisted after controlling for baseline differences and treatment effect in 
